Glycosmedia

Diabetes News Service

Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
To find out more, including how to control cookies, see here: Cookies Policy
  • News
  • Archive
  • Categories & Tags
  • Journal Watch
  • Updates
  • Education
  • Reviews
  • About us ▼
    • About Glycosmedia
    • Editorial Team
    • Frequently asked questions
    • Comments
    • Press Releases
    • Disclaimer
  • Subscribe
  • Contact

Diabetes News August 22nd 2008

August 22nd 2008

Effects of high-fat diet exposure during fetal life on type 2 diabetes development in the progeny
We conclude that a HF diet during fetal life, particularly if combined with the same insult during the suckling period, can induce the type 2 diabetes phenotype, which can be directly transmitted to the progeny even in the absence of additional dietary insults (Journal of Lipid Research)

Joslin Study Identifies Protein that Produces ‘Good’ Fat
A study by researchers at the Joslin Diabetes Center has shown that a protein known for its role in inducing bone growth can also help promote the development of brown fat, a “good” fat that helps in the expenditure of energy and plays a role in fighting obesity (Joslin Diabetes Center)

Cymbalta reduces diabetics’ DPNP for over six months
Eli Lilly and partner Boehringer Ingelheim say that treatment with the blockbuster Cymbalta, which is approved as an antidepressant and painkiller, reduces diabetic peripheral neuropathic pain for more than six months (Pharma Times)

Diabetes Research Network hoping for online recruitment boost
A recent report by market analyst Datamonitor suggested that web-based tools were the key to overcoming the recruitment drought in the established markets for clinical research. At the end of May the UKDRN launched a new website and DVD, coinciding with International Clinical Trials Day, that it hopes will achieve just that effect for diabetes research (Pharma Times)

Therapeutic approach of type 2 diabetes mellitus with GLP-1 based therapies
In patients with T2DM inadequately controlled with maximal tolerated oral multi-therapies, GLP-1 agonists are a good alternative to insulin therapy, allowing reaching a better glycaemic control together with a weight loss (PubMed)

Pharmacologic Management in Pediatric Type 1 Diabetes Mellitus
Pharmacists can play a major role in optimizing insulin drug regimens, selecting the most appropriate insulin, and counseling for adverse effects. Future studies are necessary to determine whether noninsulin therapies are effective for the treatment of T1DM. Insulin pump therapy is becoming more favorable (U.S. Pharmacist )

FDA approves Home Diagnostic diabetes test
Home Diagnostics Inc. said Tuesday it received U.S. approval to market a portable blood-sugar testing device for diabetes patients (Business Week)

Diabetic threesome (hyperglycaemia, renal function and nutrition) and advanced glycation end products: evidence for the multiple-hit agent?
Inter-individual genetic and functional variability in genes encoding enzymes and receptors involved in either the formation or the degradation of AGE could have important pathogenic, nutrigenomic and nutrigenetic consequences (PubMed)

Growing economic cost of obesity in 2008
The report titled “Growing economic costs of obesity in 2008” reveals that there has been a 137% increase since 2005 in the number of Australians who have type 2 diabetes as a result of being obese (Diabetes Australia)

Amylin Pharmaceuticals Diabetes Drug Byetta(R) the Focus of California Lawsuit
A Virginia man yesterday filed what is believed to be the first personal injury lawsuit stemming from injuries associated with the use of Byetta(R), an injectable medication for diabetes (Centre Daily)

Progress made in NHS Diabetes care
Diabetes care in the NHS is improving and focussing more on prevention, according to a report published by the Department of Health today (DoH, UK)

Five years on: delivering the diabetes national service framework
This report highlights progress over the first five years of the NSF Delivery Strategy; marking the half-way point of the implementation period. 729K PDF (DoH, UK)

Diabetes report praises GPs for improving monitoring
GP practices have helped improve diabetes care in the NHS and more people are being routinely monitored for indicators of complications, according to a report published by the Department of Health (Management in Practice, UK)

Government report glosses over diabetes care failings
This report paints too rosy a picture of the current standard of diabetes care (Diabetes UK)

Diabetes strategy worthless without obesity focus – Lamb
“But what is most striking about the report is what it doesn’t say. Almost no mention is made of the big risk that, unless we effectively tackle obesity, the number of people suffering with diabetes will almost certainly increase (Liberal Democrat Shadow Health Secretary, Norman Lamb, UK)

Arsenic Exposure and Prevalence of Type 2 Diabetes in US Adults
After adjustment for biomarkers of seafood intake, total urine arsenic was associated with increased prevalence of type 2 diabetes (JAMA)

Medicine Awarded Largest One-Time Grant by NIH to Study Community-Based Diabetes Prevention
The Mercer School of Medicine, which last year celebrated its 25th anniversary, has been awarded the largest one-time grant in the history of the school. The National Institutes of Health will provide the Department of Family Medicine at the School of Medicine with $3.1 million to conduct a five-year study of the Church-Based Diabetes Prevention and Translation program (Mercer School of Medicine, USA)

Metformin: a multitasking medication
The field of therapeutics is strewn with descriptors such as panacea, pleiotropic and holistic, so why not multitasking for metformin? (Diabetes and Vascular Disease Research)

Metformin therapy and clinical uses
As many of its actions go beyond glucose lowering, emerging evidence indicates potential benefits in other insulin-resistant states and possibly tumour suppression (Diabetes and Vascular Disease Research)

Diabetes drug users urged to see doctor
Pharmaceutical company GlaxoSmithKline (GSK) says all patients need to see their doctor as soon as possible after major changes were made to the drugs’ guidelines for use (News.com, Australia)

Eye health in Australia
A hospital perspective. 35-page PDF (AIHW, Australia)

Reproducibility of the Oral Glucose Tolerance Test in Overweight Children
Our results show poor reproducibility of the OGTT in obese youth, in particular for the 2 hour plasma glucose (Journal of Clinical Endocrinology & Metabolism)

Four decades of uncertainty
Landmark trials in glycaemic control and cardiovascular outcome in type 2 diabetes (Diabetes and Vascular Disease Research)

Endurance Exercise as a Countermeasure for Aging
The results demonstrate that reduced insulin sensitivity is likely related to changes in adiposity and physical inactivity rather than an inevitable consequence of aging (Diabetes)

Byetta woes threaten wider diabetes drug class
A new class of diabetes drugs, tipped to rake in billions of dollars, faces an uncertain future following six cases of severe pancreas inflammation linked to Amylin and Eli Lilly’s Byetta (Guardian, UK)

A comparison of diabetes clinics with different emphasis on routine care, complications assessment and shared care
In our study, clinic models which incorporate a system of structured complications screening were more likely to have met screening guidelines. Patients in a shared-care model were at least as likely to have met management targets as those attending diabetes clinics for their routine care (Diabetic Medicine)

High insulin levels are positively associated with peripheral nervous system function
Our study shows that serum insulin levels measured 120 min after an OGGT are positively associated with PNS function. High insulin levels without notably high glucose levels appear to be beneficial for the function of the PNS (Acta Neurologica Scandinavica)

New Report: Adult Obesity Rates Rise in 37 States
Rates increased for a second consecutive year in 24 states and for a third consecutive year in 19 states. Obesity Rates Now Exceed 25 Percent in More Than Half of States (Robert Wood Johnson Foundation, USA)

Weight history of patients with newly diagnosed Type 2 diabetes
The results add to the evidence that it is important to advise young patients in particular, especially women, who have gained and sustained considerable weight to curb this upward weight trend in order to prevent the development of diabetes (Diabetic Medicine)

Rosiglitazone does not increase the risk of cancer
Patients treated with rosiglitazone presented a lower rate of malignancies, i.e., serious adverse events, compared to the control groups. These beneficial effects require further investigation (American Diabetes Association)

Doctors make arm do job of pancreas
The research, conducted on the first patient a month ago, is part of an ongoing inquiry into how best to prevent diabetes in a person whose pancreas has been removed because of pancreatitis, trauma, or benign or early-stage malignant tumors (Houston Chronicle, USA)

Diabetes is found to affect bone quality
In spite of being a controversial issue, a positive association has been established between diabetes and the risk of fractures, thus indicating that both type 1 and type 2 diabetes affect bone quality (Diabetes Pro)

Oramed Pharmaceuticals Chosen to Present Oral Insulin Trial Results at EASD Conference
The fact that Oramed has been selected to present research at the EASD Conference underscores the importance of our work developing an oral insulin capsule. 2-page PDF (Oramed Pharmaceuticals)

Sitagliptin in type 2 diabetes and renal insufficiency
Sitagliptin is well tolerated and provides effective glycemic control in patients with type 2 diabetes and renal impairment (Diabetes Pro)

FDA warns on Amylin-Lilly diabetes drug Byetta
The Food and Drug Administration warned health professionals on Monday that the diabetes drug Byetta may be linked to six cases of severe pancreatitis (Market Watch)

Diabetes and anxiety in US adults
Findings from the 2006 Behavioral Risk Factor Surveillance System (Diabetic Medicine)

Adults Born Preterm Have Higher Blood Pressure, Lower Insulin Sensitivity
Because the study shows that spontaneous catch-up growth is a risk factor, it implies that “efforts aimed at the optimization of growth during infancy, childhood and adolescence are metabolically disadvantageous, especially when this is done by improving the nutrient intake, because weight gain is associated with decreased insulin sensitivity (MedScape)

Israel/Rambam/Peres Centre/Insulin for Life
Professor Hochberg and Dr Eideh asked Ron Raab if Insulin for Life Australia could donate some blood glucose monitoring strips … Supplies are now being donated regularly by Insulin for Life, Australia (Ron Raab, President, Insulin for Life, Australia)

Injection Impact Report
The American Association of Diabetes Educators (AADE) has just released results from an innovative new survey entitled the “Injection Impact Report” that highlights the level of communication between patients and healthcare providers relating to insulin injections and also spotlights how those injections can impact patients’ daily lives and treatment adherence (Patton Medical Devices)

Insulin treatment in pregnancy
Due to the teratogenic potential of many oral hypoglycemic agents, insulin injections are the primary treatment for diabetes in pregnant women. There has been insufficient study of insulin glargine in pregnancy (Drug Development Research)

Insulin Therapy for Older Adults with Diabetes
Insulin therapy can be used safely and effectively if diabetes management plans are formulated with consideration of the clinical, functional, and psychosocial contexts of an older adult (Geriatrics and Aging)

Defining human diabetic nephropathy on the molecular level: Integration of transcriptomic profiles with biological knowledge
In this review we summarize current understanding of how to link comprehensive gene expression data sets with biomedical knowledge and present strategies to build a transcriptional network of DN (PubMed)

The European perspective of type 2 diabetes prevention: diabetes in Europe
The development of efficient screening strategies for type 2 diabetes risk as well as the development of core intervention strategies for the primary prevention of type 2 diabetes should significantly enhance the ability of health care professionals to respond swiftly to the drastic increase of T2D and its burden to the society (PubMed)

Vitamin K Supplementation May Reduce Progression of Insulin Resistance in Older Men
Vitamin K supplementation for 36 months at doses that could be achieved through dietary intake may reduce progression of insulin resistance in older men (Medscape)

New website for young people with diabetes
The new website ‘myD‘ delivers information that specifically targets the online information needs of young people aged 16-25 years who are living with diabetes (Diabetes Australia)

Diabetes Buzz Day: 19 September 2008
Diabetes Buzz Day, the annual fundraising event for Diabetes Australia-NSW will be held on Friday, 19 September (Health Insite, Australia)

Insulin Aspart (NovoLog) Linked to Low Risk for Systemic Hypersensitivity Reactions
On March 14, the FDA approved safety labeling revisions for insulin aspart [rDNA origin] injection (NovoLog; Novo Nordisk, Inc) to warn of the risk for systemic hypersensitivity reactions in patients receiving this and other insulin products (Medscape)

Categories: News Pre-2012

Subscribe

subscribe-iconFREE weekly updates by email Please CLICK HERE

Platinum Sponsors

Boehringer Ingelheim Lilly

Gold Sponsors

AstraZenecaSanofi DiabetesNovo NordiskNapp Diabetes

Silver Sponsors

AmgenAbbott Diabetes CareAbout Ascensia Diabetes CareWelsh Endocrinology and Diabetes Society (WEDS)

FUNDING NOTICE

The Glycosmedia website and newsletter has been made possible with funding support from our sponsors. None of our sponsors have control over the content of the website, newsletter, apps, Twitter feed or RSS newsfeed.

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Advertisers

CRC Press

The organisations advertising in this section do not have any input into, or editorial control over the content of this website.

Join us on Facebook

Join us on Facebook

Please share Glycosmedia:

Follow us on Twitter

My Tweets

mobileGlycosmedia is also available as an App:

For iPhone and iPad | For Android devices


Sponsorship and Advertising

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Copyright © 2021 Glycosmedia Partnership